Quick answer
A 5 mg hexarelin vial dissolved in 2 mL of diluent gives 2.5 mg/mL (2,500 µg/mL, about 2.8 mM); in 1 mL it gives 5 mg/mL. The calculation is always concentration = mass ÷ volume, and the vial mass never changes, only the volume does. Pick the concentration from the lowest working point you need, split the stock into single-use aliquots, and use C1V1 = C2V2 for dilutions. The reconstitution calculator on the site does the same arithmetic. For laboratory research use only; not for human consumption.
Most reconstitution mistakes are arithmetic or unit mistakes, not technique mistakes. This guide works through the numbers for the 5 mg hexarelin vial in the order a laboratory meets them: choosing a stock concentration, tabulating the options, planning aliquots, building a dilution series, and correcting for the factors that make a label mass differ from delivered peptide. Everything is formula-based laboratory arithmetic; no biological quantity is recommended. Product facts come from the hexarelin product page, which lists a 5 mg vial, a molecular formula of C47H58N12O6 and storage at 2–8 °C, with −20 °C for long-term holding.
Start from what the assay needs, not from the vial
The common instinct is to add a convenient volume of diluent and then work out what concentration that produced. The more reliable order is the reverse. Decide the highest and lowest working concentrations the experiment will use, decide how much volume each well, tube or preparation takes, and then choose a stock that allows all of them to be prepared by dilution with a pipetting volume that can be measured accurately. A concentrated stock keeps the added volume small relative to the assay, which matters when the vehicle (for example benzyl alcohol in bacteriostatic water) could interfere with the readout.
The three formulas
- Concentration (mg/mL) = vial mass (mg) ÷ diluent volume (mL).
- Molarity (mol/L) = concentration (g/L) ÷ molecular weight. With a molecular weight of about 887 g/mol, 1 mg/mL is about 1.13 mM.
- Dilution: C1V1 = C2V2. Stock concentration times the volume taken equals final concentration times final volume.
Because 1 mg/mL equals 1 g/L and also 1,000 µg/mL, the three units move together by factors of ten, which is where most slips happen. The molecular weight used here is calculated from the formula on the product page; the research overview quotes "about 887 Da" for the same compound.
Concentration table for the 5 mg vial
| Diluent volume | mg/mL | µg/mL | Molarity |
|---|---|---|---|
| 1 mL | 5 | 5,000 | 5.64 mM |
| 1.5 mL | 3.33333 | 3,333 | 3.76 mM |
| 2 mL | 2.5 | 2,500 | 2.82 mM |
| 2.5 mL | 2 | 2,000 | 2.25 mM |
| 3 mL | 1.66667 | 1,667 | 1.88 mM |
| 4 mL | 1.25 | 1,250 | 1.41 mM |
| 5 mL | 1 | 1,000 | 1.13 mM |
The product page's own example is the 2 mL row: 2.5 mg/mL, so a 40 µL portion contains 100 µg. That row is a good default when the protocol works in micrograms, because the volumes involved are large enough to pipette accurately. The 1 mL row halves the diluent and doubles the concentration, which suits designs that will be diluted heavily. The reconstitution calculator returns any other combination, and the principles behind it are explained in reconstitution calculator guide and peptide reconstitution volume calculations.
Aliquot planning
Freezing single-use portions avoids repeated freeze–thaw cycles on one vial. The volume of each portion follows from the mass wanted per portion and the stock concentration: volume (µL) = mass (µg) ÷ concentration (µg/µL). The table applies this to the two most useful stock concentrations.
| Mass wanted per aliquot | Volume of 2.5 mg/mL stock | Volume of 1 mg/mL stock |
|---|---|---|
| 25 µg | 10 µL | 25 µL |
| 50 µg | 20 µL | 50 µL |
| 100 µg | 40 µL | 100 µL |
| 250 µg | 100 µL | 250 µL |
| 500 µg | 200 µL | 500 µL |
Two cautions. A vial is never fully recoverable, because some liquid stays on the stopper and glass, so plan one fewer aliquot than the arithmetic allows. And label every aliquot with compound, lot, concentration, date and freeze count at the time it is made; the logic is in how to reconstitute a lyophilized peptide.
A serial dilution to nanomolar working solutions
Cell and isolated-tissue studies of hexarelin have reported working concentrations from 1 nM to about 1 µM (Ma and colleagues, 2012; Zhao and colleagues, 2016). Reaching those from a millimolar stock needs a dilution factor of roughly a thousand to a million, which should never be done in a single step. A workable scheme from the 2.5 mg/mL stock:
| Step | From | To | Dilution factor | Result |
|---|---|---|---|---|
| 1 | 2.5 mg/mL stock (about 2.8 mM) | 100 µM intermediate | about 1:28 | 100 µM |
| 2 | 100 µM | 1 µM | 1:100 | 1 µM |
| 3 | 1 µM | 10 nM | 1:100 | 10 nM |
| 4 | 10 nM | 1 nM | 1:10 | 1 nM |
Each intermediate is made fresh from the one before it in low-binding tubes, with a new tip at each step and thorough but gentle mixing. Mixing by repeated pipetting is better than vortexing for peptide solutions. Dilute solutions lose a measurable fraction of peptide to plastic and glass (Goebel-Stengel and colleagues, 2011), so the lower rungs should be prepared on the day of the experiment and not stored.
Corrections that change the real concentration
- Net peptide content. The vial label states mass of lyophilized material. Counter-ions and residual water account for part of it, so peptide content is lower than label mass. HPLC purity (≥98% on the product page) describes the fraction of the chromatographic signal, not net content. See understanding HPLC purity.
- Volume displacement. The dissolved peptide adds a small volume to the liquid. At 5 mg in 2 mL the effect is negligible for most work, but it is not zero.
- Recovery. Liquid left in the syringe dead space, on the stopper and on the vial wall is lost; rinse the closure down once if full recovery matters.
- Adsorption. Loss to surfaces rises as concentration falls (Goebel-Stengel and colleagues, 2011).
- Matrix. Serum-containing media contain peptidases that act on the GHRP family (Thomas and colleagues, 2012), so nominal concentration may not be maintained over a long exposure.
Where exact delivered concentration is the critical variable, an amino-acid analysis or quantitative LC-MS on the stock is the only direct answer. Short of that, state in the methods that concentrations are nominal, based on label mass and measured diluent volume, so that readers can judge how much weight the stated figure can bear. This honesty costs one sentence and prevents the most common source of irreproducibility, which is a number that looks exact but rests on an unstated assumption about what was in the vial.
Three worked planning scenarios
The scenarios below use only the arithmetic above and are illustrations of method, not protocol recommendations.
| Scenario | Constraint | Planning logic |
|---|---|---|
| Receptor-binding or signaling assay in a 96-well plate | Many wells, small volumes, wide concentration range | Make a high-concentration stock (the 1 mL row), then run a half-log or ten-fold series; keep the added stock volume under about 1% of well volume so vehicle effects stay constant across wells |
| Perfused isolated tissue | One large reservoir, single working concentration, nanomolar range | Dilute through two intermediates to the target, prepare the whole reservoir at once, and sample the perfusate at the start and end to document the delivered concentration |
| Repeated experiments over several weeks from one lot | Consistency between runs matters more than speed | Prepare the stock once, freeze single-use aliquots of identical volume, and thaw one per experiment so every run starts from the same preparation |
In every case the point is the same: fix the quantity that must stay constant, such as vehicle volume or stock preparation, and let the others vary in a controlled way. Writing the plan as a short table before opening the vial catches most unit errors before they cost material.
Diluent choice and what it does to the numbers
The diluent changes the vehicle, not the peptide arithmetic. Bacteriostatic water contains a preservative and suits a stock that will be entered repeatedly; sterile water suits a stock divided and frozen the same day, or an assay in which the preservative could interfere. Whatever is used, the concentration formula is identical. What changes is the vehicle control: if the stock is in bacteriostatic water, the control wells must receive the same volume of the same diluent. Background on the diluent is in bacteriostatic water explained.
What to record at reconstitution
| Field | Example entry | Why it is needed |
|---|---|---|
| Compound and lot | Hexarelin, lot number from the vial label | Links the stock to its certificate |
| Vial mass | 5 mg (label) | Starting point of every calculation |
| Diluent and volume | Name of diluent, volume added, device used | Reproduces the concentration |
| Concentration | mg/mL and mM | Both are needed for dilution planning |
| Date, preparer, storage | Date, initials, location | Traceability |
| Aliquot map | Number of aliquots, volume and freeze count each | Prevents silent refreezing |
With these six fields in the notebook, a result that drifts weeks later can be traced to a preparation instead of guessed at.
Common errors checklist
- Mixing mg and µg: 2.5 mg/mL is 2,500 µg/mL, not 250.
- Mixing mL and µL when computing aliquot volume.
- Using vial mass from a different size, such as a 10 mg label, in a 5 mg calculation.
- Adding diluent by weight or by eye instead of by a calibrated pipette or syringe.
- Calculating molarity from the wrong molecular weight, for example a salt form or another GHRP.
- Recording the volume added but not the date, lot and diluent.
For the handling side of the same workflow, including solvent choice and visual checks, see the hexarelin research overview and the stability evidence summarized in the companion article on hexarelin half-life and stability.
Related reading
- Hexarelin research overview
- Reconstitution calculator guide
- How to reconstitute a lyophilized peptide
- Hexarelin purity testing
- Where to buy hexarelin for research
- Research peptide catalog
Frequently asked questions
How much diluent should go into a 5 mg hexarelin vial?
It depends on the stock concentration the experiment needs. The product page gives 2 mL for 2.5 mg/mL and 1 mL for 5 mg/mL. The vial mass is fixed; only the volume sets the concentration.
What is the molarity of hexarelin at 2.5 mg/mL?
About 2.8 mM, using a molecular weight of roughly 887 g/mol from the formula C47H58N12O6.
How many micrograms are in 40 µL of a 2.5 mg/mL hexarelin stock?
100 µg, because 2.5 mg/mL equals 2.5 µg/µL and 40 µL × 2.5 µg/µL = 100 µg. This matches the example on the product page.
How do I make a 1 µM working solution from the stock?
Dilute in steps instead of one jump: for example about 1:28 to reach 100 µM, then 1:100 to reach 1 µM, using C1V1 = C2V2 at each step and low-binding tubes.
Does 98% purity mean 98% of the vial is hexarelin by mass?
No. HPLC purity is the share of the chromatographic signal. Counter-ions and water also contribute to vial mass, so net peptide content is lower.
Should reconstituted hexarelin be aliquoted?
Yes, if it will be used more than a few times. Freeze single-use portions at −20 °C, label them, and thaw each only once.
Where is the calculator?
The reconstitution calculator is linked from the site navigation and performs these calculations for any vial size and diluent volume.
Related reading: Hexarelin Preclinical Studies: A Review by Model, Hexarelin Lab Applications: Assays and Model Systems, Hexarelin Research Profile: Chemistry and Key Studies.
References
- Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. doi:10.1371/journal.pone.0035265
- Zhao Y, Zhang X, Chen J, Lin C, Shao R, Yan C, et al.. Hexarelin Protects Rodent Pancreatic Β-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro. PLoS One. 2016;11(2):e0149730. doi:10.1371/journal.pone.0149730
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Thomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012;84(23):10252-9. doi:10.1021/ac302034w
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
